About the Company
We do not have any company description for Bioventus Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
1190
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Bioventus Inc.
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT
Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum ...
Bioventus Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 ...
Bioventus Inc. to Report Fourth Quarter Fiscal 2024 Financial ... - Nasdaq
Bioventus Inc. will announce Q4 fiscal 2024 financial results on March 11, 2025, with a conference call at 8:30 AM ET. Bioventus Inc. announced it will report its fourth quarter financial results ...
Shareholders Can Be Confident That Bioventus' (NASDAQ:BVS) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like Bioventus Inc.'s ( NASDAQ:BVS ) ...
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ETCompany ParticipantsDave Crawford - Investor RelationsRob Claypoole ...
Bioventus gets FDA clearance for two pain-management devices
Bioventus, a Durham-based health care company, has received regulatory permission to begin marketing two medical devices that treat chronic pain. The U.S. Food and Drug Administration granted 510(k) ...
Bioventus Inc - (BVS) Price Target Increased by 28.57% to 4.59
The average one-year price target for Bioventus Inc - (NASDAQ:BVS) has been revised to 4.59 / share. This is an increase of 28.57% from the prior estimate of 3.57 dated August 1, 2023. The price ...
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Bioventus’ full-year 2024 worldwide revenue totaled $573.3 million, an increase of 11.9% compared to the prior year. On an organic* basis, revenue increased 14.4%, driven by double-digit growth ...
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement ...
Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q1 2023 Earnings Conference Call May 16, 2023 5:00 PM ETCompany ParticipantsDave Crawford - VP, IRTony Bihl - CEOMark Singleton ...
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus ...
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm December 26, 2023 09:00 PM Eastern ...
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard ...
If you purchased or otherwise acquired Bioventus securities, including pursuant to the IPO, and/or would like to discuss your legal rights and options please visit bioventus inc. shareholder class ...
Similar Companies
Loading the latest forecasts...